Table 3. Frequencies and intensities of IgE reactivity to purified marker allergens in AD patients detected by allergen chip technology.
| No. | Allergen | All AD | Severe AD | Moderate AD | Severe AD | Moderate AD | Allergen family, Function, CCD | Severe AD | Moderate AE |
|---|---|---|---|---|---|---|---|---|---|
| median (range) | median (range) | Rhinoconjuctivitis | Rhinoconjuctivitis | ||||||
| n = 179 | n = 53 | n = 126 | IgE (ISU)a) | IgE (ISU) | and/or asthma | and/or asthma | |||
| n (%) | n (%) | n (%) | n = 47 n (%) | n = 96 n (%) | |||||
| 1 | rFel d 1 | 93 (52) | 36 (68) ** | 57 (45) | 4.3 (0.31–134.17) | 4.14 (0.35–127.92) | Uteroglobin | 36 (77) ** | 51 (53) |
| 2 | rBet v 1 | 93 (52) | 33 (62) | 60 (48) | 12.83 (0.33–120.37) | 8.96 (0.34–102.94) | PR-10 | 32 (68) | 51 (53) |
| 3 | rPhl p 1 | 79 (44) | 24 (45) | 55 (44) | 2.11 (0.31–48.74) | 2.43 (0.31–56.91) | β-Expansin | 23 (49) | 45 (47) |
| 4 | nPhl p 4 | 51 (29) | 22 (42) * | 29 (23) | 1.53 (0.31–16.6) | 1.25 (0.39–26.31) | Grass-group 4, CCD | 21 (45) * | 26 (27) |
| 5 | rPhl p 5b | 47 (26) | 12 (23) | 35 (28) | 4.83 (0.61–28.58) | 3.41 (0.32–86.9) | Grass-group 5 | 11 (23) | 32 (33) |
| 6 | rCan f 1 | 43 (24) | 16 (30) | 27 (21) | 14.28 (0.44–111.13) | 6.91 (0.61–121.54) | Lipocalin | 16 (34) | 25 (26) |
| 7 | rFel d 4 | 43 (24) | 15 (28) | 28 (22) | 9.32 (0.45–118.56) | 2.9 (0.34–55.56) | Lipocalin | 15 (32) | 27 (28) |
| 8 | rCan f 5 | 40 (22) | 14 (26) | 26 (21) | 2.29 (0.54–28.17) | 3.62 (0.35–27.48) | Arginine Esterase | 14 (30) | 23 (24) |
| 9 | rPhl p 6 | 35 (20) | 12 (23) | 23 (18) | 0.89 (0.38–14.56) | 2.66 (0.36–33.03) | Grass-group 5/6 | 11 (23) | 21 (22) |
| 10 | nArt v 1 | 35 (20) | 12 (23) | 23 (18) | 1.14 (0.34–43.7) | 1.39 (0.32–38.99) | Defensin-like protein | 12 (26) | 21 (22) |
| 11 | rDer p 2 | 34 (19) | 13 (25) | 21 (17) | 33.79 (0.57–131.74) | 5.18 (0.35–103.86) | Group 2 mite-allergen | 12 (26) | 20 (21) |
| 12 | rPhl p 2 | 31 (17) | 6 (11) | 25 (20) | 9.72 (0.74–27.15) | 5.59 (0.36–33.3) | Grass-group 2/3 | 5 (11) * | 24 (25) |
| 13 | rCan f 6 | 26 (15) | 10 (19) | 16 (13) | 2.11 (0.4–14.01) | 1.72 (0.3–7.25) | Lipocalin | 10 (21) | 15 (16) |
| 14 | nDer p 1 | 25 (14) | 11 (21) | 14 (11) | 4.99 (0.62–18.63) | 0.88 (0.4–31.58) | Group 1 mite- allergen | 10 (21) | 13 (14) |
| 15 | rCan f 2 | 25 (14) | 9 (17) | 16 (13) | 1.03 (0.4–49.04) | 2.09 (0.34–41) | Lipocalin | 9 (19) | 15 (16) |
| 16 | rDer p 4 | 18 (10) | 10 (19) * | 8 (6) | 0.87 (0.32–3.57) | 0.71 (0.32–4.87) | Group 4 mite-allergen | 9 (19) * | 7 (7) |
| 17 | rDer p 23 | 18 (10) | 7 (13) | 11 (9) | 29.98 (0.7–98.11) | 14.16 (1.69–43.88) | Chitin-binding domain | 6 (13) | 11 (12) |
| 18 | rCan f 4 | 14 (8) | 6 (11) | 8 (6) | 8.65 (0.45–64.14) | 12.25 (0.39–25.9) | Lipocalin | 6 (13) | 7 (7) |
| 19 | rDer p 10 | 12 (7) | 8 (15) ** | 4 (3) | 0.49 (0.3–3.8) | 2.57 (0.44–3.47) | Tropomyosin | 7 (15) * | 3 (3) |
| 20 | rDer p 5 | 11 (6) | 6 (11) | 5 (4) | 1.48 (0.44–93.01) | 2.47 (0.34–87.36) | Group 5 mite-allergen | 6 (13) | 4 (4) |
| 21 | rDer p 7 | 9 (5) | 4 (8) | 5 (4) | 1.82 (0.37–3.71) | 11.65 (0.75–22.5) | Group 7 mite-allergen | 4 (9) | 4 (4) |
| 22 | rDer p 11 | 8 (4) | 4 (8) | 4 (3) | 0.42 (0.3–1.62) | 0.86 (0.31–1.09) | Group 11 mite-allergen | 3 (6) | 4 (4) |
| 23 | rDer p 15 | 5 (3) | 3 (6) | 2 (2) | 0.33 (0.32–16.44) | 0.7 (0.68–0.71) | Chitin-binding domain | 3 (6) | 2 (2) |
| 24 | rDer p 21 | 6 (3) | 3 (6) | 3 (2) | 2.52 (0.86–71.48) | 47.28 (11.23–80.02) | Group 21 mite-allergen | 3 (6) | 3 (3) |
| 25 | rDer p 18 | 6 (3) | 2 (4) | 4 (3) | 3.76 (1.85–5.67) | 1.21 (0.32–8.22) | Chitin-binding domain | 2 (4) | 4 (4) |
| 26 | rDer p 14 | 4 (2) | 1 (2) | 3 (2) | 0.68 (0.68) | 0.56 (0.39–1.28) | Vitellogenin | 1 (2) | 3 (3) |
| 36 (77) |
a) MeDALL allergen chip, reference range ≥ 0.3 ISU
Significant differences between severe and moderate AD patients are indicated * p<0.05, ** p<0.01. Taken into account the number of tested variables (n = 26) the expected number of allergens to be significant at p level <0.05 by chance is 1.3.
AD = atopic dermatitis, CCD = cross-reactive carbohydrate determinates, n = natural, r = recombinant